A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women.

Background: Pregnancy-related venous thromboembolism (VTE) is one of the leading causes of maternal morbidity and mortality.

Objectives: To review the epidemiology, and humanistic and economic burden of pregnancy-related VTE.

Search Strategy: Medline, the Cochrane Central Register of Controlled Trials, Econlit, Science Direct, JSTOR, Oxford Journals, and Cambridge Journals were searched for reports published between January 2000 and December 2012.

Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology.

Low molecular weight heparins have demonstrated superiority over coumarins in the extended treatment of cancer-associated thrombosis and are recommended as first-line therapy in clinical guidelines. Non-vitamin K oral antagonists are yet to be evaluated against low molecular weight heparin for this indication. Nevertheless, a perception that patients favor oral anticoagulants over injections may lead to an increased prescribing of warfarin or non-vitamin K oral antagonists despite the evidence gap.

The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review.

The objective of this study was to present evidence on the epidemiology, health outcomes and economic burden of cancer-related venous thromboembolism (VTE). Medline, Cochrane Central Register of Controlled Trials, Econlit, Science Direct, JSTOR, Oxford Journals and Cambridge Journals were searched. The systematic literature search was limited to manuscripts published from January 2000 to December 2012.

Trends in influenza vaccination coverage rates in Germany over five seasons from 2001 to 2006.

Background: To assess influenza vaccination coverage from 2001 to 2006 in Germany, to understand drivers and barriers to vaccination and to identify vaccination intentions for season 2006/07.

Methods: 9,990 telephone-based household surveys from age 14 were conducted between 2001 and 2006. Essentially, the same questionnaire was used in all seasons.

Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11).

Question Under Study: despite the increasing prevalence of type 2 diabetes, its financial burden on the Swiss healthcare system remains unclear. Our aim was to determine the cost of self-monitoring of blood glucose (SMBG) in reducing diabetic complications by comparing the direct costs to the Swiss statutory health insurance system of diabetic complications in SMBG users vs. nonusers.

Developments in influenza vaccination coverage in England, Scotland and Wales covering five consecutive seasons from 2001 to 2006.

This study aims at assessing trends in influenza vaccination coverage from 2001 to 2006 in Great Britain, at understanding drivers and barriers to vaccination and at identifying vaccination intentions for influenza season 2006/2007. In seasons 2001/2002 to 2005/2006, telephone-based household surveys representative of the population from age 16 were conducted, with about 2000 interviews per season (10,095 in total). Overall influenza vaccination coverage rate in Great Britain reached 25.

Influenza vaccination coverage rates in Europe--covering five consecutive seasons (2001-2006) in five countries.

Objective: To understand potential drivers and barriers to influenza vaccination in the general population.

Methods: 47 982 household surveys were conducted in five European countries between 2001 and 2006.

Results: Overall influenza vaccination coverage increased over the years and reached 26.

Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.

Objective: The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI). The EPHESUS pharmacoeconomic analysis was performed to evaluate the cost-effectiveness of eplerenone in the Swiss setting.

Materials And Methods: A total of 6,632 patients with LVSD and heart failure after AMI were randomized to eplerenone or placebo and followed for a mean of 16 months.